一 | (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed. China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval. A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country. Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category. This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading. At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly. To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong. The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions. In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total. (By Tang Yuxian) 
。 8月25日消息，据报道，美国总统特朗普近日宣布，自2027年1月1日起，将把加拿大输美汽车、卡车、汽车零部件和钢铁的进口关税提高至50%。
加拿大总理卡尼回应，称加拿大绝不会接受任何损害主权和产业利益的"附属国协议"。 这是继8月23日美国正式对约200亿美元加拿大商品征收50%关税后，美方再次升级贸易施压。此前双方旨在避免关税生效的贸易谈判已于22日宣告破裂。 特朗普在社交媒体发文，呼吁加拿大企业将生产线迁往美国以避免高额关税，并称在美国生产相关产品将享受“零关税”待遇。
他同时再次称呼卡尼为“州长”，威胁“必须有人让加拿大乖乖听话”。 卡尼24日在魁北克举行记者会，直指美方谈判态度是将加拿大视作“美国的附属”，要求加拿大产业长期处于竞争劣势。 他表示，特朗普希望通过“不公平的条件”削弱加拿大钢铁、铝和汽车三大支柱产业。“双方完全有可能达成互利协议，但前提是协议必须尊重加拿大的主权和独立，而不是为了美国的短期利益拆毁加拿大产业。”
据卡尼透露，谈判破裂并非单一原因。双方曾讨论将美国汽车关税降至15%，但美方拒绝把这一优惠扩大至中型和重型卡车，而这类车型正是福特汽车位于多伦多郊区工厂正在生产的重要产品。 更令加拿大无法接受的是，美方还要求限制加拿大与第三国签署贸易协议，并在文化及法语事务上提出附加条件。 美国贸易代表杰米森·格里尔则给出截然不同的说法。
二 | 他表示，是加拿大在最后关头提出新要求，导致接近完成的协议草案流产。
三 | 按照格里尔的说法，这份协议原本将降低汽车、钢铁、铝材和木材关税，并建立出口管制、数字贸易及联合关税合作机制，同时启动《美墨加协定》的正式续约谈判。该协定由特朗普第一任期推动签署，但特朗普今年拒绝续签。 就在记者会结束数分钟后，特朗普再次发文，继续称呼卡尼为“州长”，并抨击安大略省省长道格·福特，写道：“必须有人让这些小丑乖乖听话，否则加拿大将面临更严重的后果。
四 | ”
五 |
Current article:http://8i5c.nuotingqinbeimaeijin.cfd/news/20260826_328.html
Published on:15:58:31
